CRVS Stock — Corvus Pharmaceuticals Inc.: Cash, EV, Pipeline

What they do

We are a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. We believe our proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers.

Source: 10-K FY2025 via SEC EDGAR

Share price

$10.54

Market cap

$886.6M

Cash

$202.9M

Enterprise value

$683.7M

Balance sheet

Cash	$202.9M
Debt	$0.0M
Net cash	$202.9M
Enterprise value	$683.7M
Basic shares	84.3M shares
Fully diluted shares	106.1M shares
Fully diluted market cap	$1,117.8M
Cash per share	$2.41
Quarterly burn	$15.4M
Cash runway	14.0 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

84.1M

Pre-funded warrants

8.3M

Options

13.3M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.4M

FDSO

106.1M

Cap table as of 2026-08-06.

Price history

Loading CRVS daily closes…

Loading price history…

Next catalyst

soquelitinib · Est. Mar 1, 2027 · guidance midpoint · guided in 8 wks

Recently reported

Soquelitinib Phase 2 Negative · 2026-11-04

Primary: One-year safety and efficacy of soquelitinib 200 mg twice per day in the NIAID-led Phase 2 trial in autoimmune lymphoproliferative syndrome (ALPS) — All three patients completed one year of treatment, were able to discontinue background medications including steroids, and reported improvement in ALPS related systemic symptoms

· Three ALPS patients enrolled as of August 3, 2026 and completed one year of treatment

· No grade 3 or 4 adverse events

· No interruptions in therapy

· All three patients discontinued background medications including steroids

Safety: Well tolerated, with no grade 3 or 4 adverse events and no interruptions in therapy

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Mar 1, 2027 in 8 wks guidance midpoint	soquelitinib Angel Pharmaceuticals Phase 2 trial in asthma (China) - initiation guided	Phase 2	asthma (China) - initiation guided	early 2027
Jul 13 - Aug 24 in 8 mo	Soquelitinib	Phase 2	Atopic Dermatitis; Atopic Dermatitis Eczema; Eczema	late 2026 Est. Nov 7, 2026 · guidance midpoint
Dec 13, 2027 - Jan 24, 2028 in 13 mo	Soquelitinib	Phase 3	Peripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic T-cell Lymphoma; Follicular T-Cell Lymphoma	—
Jan 12 - Feb 23 in 14 mo	Soquelitinib	Phase 1	Hidradenitis Suppurativa	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

soquelitinib

Phase 3 · Active

Aliases CPI-818

Target ITK (interleukin 2 inducible T cell kinase)

Partnerships Angel Pharmaceuticals (partner in China; conducting Phase 1b/2 trial in atopic dermatitis)

Indications

relapsed peripheral T-cell lymphoma (Phase 3)
atopic dermatitis (Phase 2)

Status note Lead product candidate. Enrolling a potentially registrational Phase 3 trial in relapsed peripheral T-cell lymphomas; randomized placebo-controlled Phase 2 in atopic dermatitis.

ciforadenant

Phase 1 · Active Modality: oral small molecule

Target A2A receptor (adenosine)

Partnerships Vernalis (R&D) Limited (exclusive worldwide license, Feb 2015; $3.0M milestone paid Feb 2017; tiered royalties)

Indications

metastatic renal cell cancer (1L, with ipilimumab + nivolumab) (Phase 1)

Status note A2A adenosine receptor antagonist. Being evaluated with the Kidney Cancer Research Consortium in an open-label Phase 1b/2 trial as first-line therapy for metastatic RCC in combination with ipilimumab and nivolumab.

mupadolimab

Phase 1 · Active Modality: monoclonal antibody

Target CD73

Indications

cancers and infectious diseases (broad) (Phase 1)

Status note Humanized monoclonal antibody targeting CD73. Company deferred initiating a potential Phase 2 randomized trial to prioritize soquelitinib and ciforadenant; remains in clinical development.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Soquelitinib
Lead indication	Peripheral T-Cell Lymphoma, Not Otherwise Specified
Lead phase	Phase 3
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06561048	Phase 3	Recruiting	Sponsor	CRVS	—	Peripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic T-cell Lymphoma; Follicular T-Cell Lymphoma	—
NCT07441395	Phase 2	Recruiting	Sponsor	CRVS	—	Atopic Dermatitis; Atopic Dermatitis Eczema; Eczema	late 2026 Est. Nov 7, 2026 · guidance midpoint
NCT03952078	Phase 1	Active, not recruiting	Sponsor	CRVS	—	T-cell Lymphoma	—
NCT07828860	Phase 1	Recruiting	Sponsor	Corvus Pharmaceuticals, Inc.	—	Hidradenitis Suppurativa	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Corvus Pharmaceuticals, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	7,165,006	no change	2.03%	2026-08-14
Vivo Capital	2,805,816	no change	3.83%	2026-08-14
Perceptive Advisors	2,667,441	+375,000	0.62%	2026-08-14
Braidwell LP	2,126,298	+373,500	1.18%	2026-08-14
Boxer Capital	1,100,000	no change	1.24%	2026-08-14
RA Capital Management	450,000	no change	0.06%	2026-08-14
Sphera Biotech	244,961	-3,000	0.52%	2026-08-14
ADAR1 Capital Management	117,101	+29,200	0.08%	2026-08-14
Logos Global Management	0	-450,000	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

CRVS — Corvus Pharmaceuticals Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

CRVS — Corvus Pharmaceuticals Inc.